Every 10-Q that Zevra Therapeutics Inc (ZVRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVRA filings page.
Zevra Therapeutics, Inc. reported strong results for the six months ended June 30, 2026, with net revenue of $75.9 million and net income of $46.6 million, driven primarily by sales of MIPLYFFA and contributions from an expanded access program and AZSTARYS royalties.
MIPLYFFA generated $54.9 million and OLPRUVA $0.5 million in product sales over six months, while the global expanded access program contributed $19.1 million, net of clawback and related adjustments. A $43.3 million gain was recorded from the sale of SDX-related assets to Commave, after required sharing with Aquestive.
The balance sheet strengthened meaningfully: cash and cash equivalents rose to $145.3 million and all long-term debt of $61.9 million at December 31, 2025 was fully repaid in March 2026. Total liabilities fell to $85.1 million and stockholders’ equity increased to $217.7 million. Zevra also notes a July 2026 negative CHMP opinion on the MIPLYFFA marketing application in Europe, for which it has requested re-examination, and continues a Phase 3 trial of celiprolol in VEDS.
Zevra Therapeutics, Inc. reported a strong turnaround for the quarter ended March 31, 2026, driven by higher product sales and a major asset sale. Net revenue rose to $36.2 million, led by MIPLYFFA sales of $24.6 million and expanded access program revenue of $10.2 million. The company recorded a $43.3 million gain from selling its serdexmethylphenidate portfolio and related rights to Commave.
After factoring in this gain and one-time financing charges, Zevra generated net income of $37.9 million, compared with a loss a year earlier. It used the proceeds to fully repay approximately $63.1 million of long‑term debt, ending the quarter debt‑free with $95.6 million of cash and cash equivalents and total investments of $141.2 million. As of May 1, 2026, it had 59.1 million shares of common stock outstanding.
Zevra Therapeutics (ZVRA) reported sharply improved results in its Q3 2025 10-Q. Revenue rose to $26.1 million from $3.7 million a year ago, driven mainly by MIPLYFFA sales. The company posted a small net loss of $0.5 million for the quarter versus a $33.2 million loss last year.
For the nine months ended September 30, 2025, revenue reached $72.3 million, and net income was $71.1 million, aided by a $148.3 million gain from selling a priority review voucher. Results also reflect a $58.7 million intangible asset impairment and $11.7 million in inventory write-downs. MIPLYFFA generated $22.4 million in Q3 and $61.0 million year-to-date; OLPRUVA contributed $0.1 million in Q3 and $0.5 million year-to-date. The AZSTARYS license produced $1.2 million in Q3.
Liquidity strengthened: cash and cash equivalents were $54.4 million with $175.9 million in investment securities at fair value, and stockholders’ equity increased to $133.2 million. Long-term debt stood at $61.3 million under the 2024 term loan facility. As of November 3, 2025, 56,297,535 shares of common stock were outstanding.
Zevra Therapeutics reported a net income of $74.7 million for the quarter ended June 30, 2025, driven largely by a $148.3 million gain on the sale of a transferable priority review voucher (PRV). Product revenue rose to $25.9 million for the quarter and $46.3 million year-to-date, led by MIPLYFFA sales of $21.5 million in the quarter.
The balance sheet strengthened with $47.7 million in cash and approximately $170.0 million in fair-value securities, bringing total assets to $256.3 million and stockholders' equity to $117.2 million. Material charges included a $58.7 million intangible-asset impairment related to OLPRUVA and an $11.7 million inventory write-down. Long-term debt was $60.7 million. The company disclosed ongoing litigation concerning the AZSTARYS license agreement.